Beyond Air Stock Earnings Reports

Beyond Air reported strong commercial momentum in Q1 FY2026 (quarter ended June 30, 2025): revenue rose 157% year-over-year to $1.8M and 50% sequentially. Management reaffirmed full-year revenue guidance of $12M–$16M. Key commercial drivers include expanded U.S. access via GPOs (added to Premier; already on Vizient), growing hospital adoption (dozens of hospitals), and international distribution partnerships covering >30 countries (training/demo revenue has begun; material hospital wins may follow in coming quarters). The company is prioritizing regulatory clearance and launch of LungFit PH II (Gen II) in calendar 2026 (management views Gen II as the primary strategic focus and a major market-share driver). Cost control produced meaningful improvements: operating expenses were reduced ~40% YoY, R&D and SG&A both declined, net cash burn fell >60% YoY to $4.7M for the quarter, and cash and marketable securities were $6.5M at quarter-end, which management says should fund operations well into calendar 2026 if revenue and cost trends hold. Early-stage programs (Beyond Cancer, NeuroNOS, LungFit GO pre-IDE) continue to progress but with no new near-term milestones beyond previously disclosed plans. Management reiterated the typical 4–12 month sales cycle from first contact to hospital implementation and cautioned that while Premier will ease access and accelerate conversations, meaningful revenue impact from some partnerships and tenders will often materialize over multiple quarters.